research British Association of Dermatology Meeting 1966: Dermatological Research and Case Studies
The meeting discussed various skin conditions, treatments, and unusual cases, highlighting the effectiveness of tetracycline in treating rosacea.
Search
forLearn
0 / 0 results — no results
Research
5 / 641 results research Mutations in Gamma-Secretase Subunit-Encoding PSENEN Underlie Dowling-Degos Disease Associated with Acne Inversa
PSENEN gene mutations can cause both Dowling-Degos disease and acne inversa.
research Diseases Associated With Hidradenitis Suppurativa: Part 2 of a Series on Hidradenitis
Hidradenitis suppurativa is linked to various diseases like obesity, depression, arthritis, and Crohn's disease, but often occurs alone.
research Pleiotropic Role of Notch Signaling in Human Skin Diseases
Notch signaling disruptions can cause various skin diseases.
research Index
The document is a detailed guide on skin conditions and treatments for dermatologists.
Community Join
3 / 3 resultscommunity When could we expect pp405 to hit the market?
PP405 is expected to finish Phase 2 trials in late 2025, with potential market availability around 2028-2029 if all goes well. Current treatments like finasteride and minoxidil are still popular, while new options like KX-826 and Breezula are anticipated soon.
community Update : 7 months on DUT every other day
The user experienced significant hair improvement after 7 months of using Dutasteride (DUT) every other day, with no side effects, unlike previous experiences with Finasteride (FIN) and Minoxidil (MIN). The user plans to continue DUT for up to 24 months and is considering a hair transplant for further results.
community (M23)Been on DUT for a year and 1 month- so is a transplant not a good option if DUT doesn’t work🤷♂️
The user has been using Dutasteride for over a year for hair loss and is considering a hair transplant if it doesn't work. Suggestions include adding Minoxidil and microneedling, but some advise against a transplant as the current treatment seems effective.